You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameClindamycin
Accession NumberDB01190  (APRD00566)
TypeSmall Molecule
GroupsApproved
Description

Clindamycin is a semisynthetic lincosamide antibiotic that has largely replaced lincomycin due to an improved side effect profile. Clindamycin inhibits bacterial protein synthesis by binding to bacterial 50S ribosomal subunits. It may be bacteriostatic or bactericidal depending on the organism and drug concentration.

Structure
Thumb
Synonyms
SynonymLanguageCode
7-CDLNot AvailableNot Available
7(S)-Chloro-7-deoxylincomycinNot AvailableNot Available
Cleocin (tn)Not AvailableNot Available
ClindamicinaSpanishINN
ClindamycinNot AvailableNot Available
ClindamycineFrenchINN
ClindamycinumLatinINN
Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-alpha-D-galacto-octopyranosideNot AvailableNot Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cleocin Hydrochloridecapsule75 mgoralPharmacia and Upjohn Company1970-05-22Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Cleocincream20 mg/gvaginalPharmacia and Upjohn Company1992-08-11Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Cleocinsuppository100 mgvaginalPharmacia and Upjohn Company1999-08-13Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Evoclinaerosol, foam10 mg/gtopicalStiefel Laboratories Inc2009-10-052015-06-30Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindagelgel10 mg/mLtopicalGalderma Laboratories, L.P.2000-11-272015-07-01Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindagelgel1 g/10mLtopicalOnset Dermatologics LLC2013-11-25Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Evoclinaerosol, foam10 mg/gtopicalPrestium Pharma, Inc.2014-08-19Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycin Phosphatesolution10 mg/mLtopicalGreenstone LLC1980-06-20Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycin Phosphategel10 mg/gtopicalGreenstone LLC1987-01-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycin Phosphatelotion10 mg/mLtopicalGreenstone LLC1989-05-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycin Phosphatecream20 mg/gvaginalGreenstone LLC1992-08-11Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindessecream20 mg/gvaginalTher Rx Corporation2009-11-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Clindamycin Phosphatesolution10 mg/mLtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.1997-06-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycin Phosphategel10 mg/gtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.2010-01-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycin Phosphatelotion10 mg/mLtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.2002-01-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycin Phosphatecream20 mg/gvaginalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.2004-12-27Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycininjection, solution150 mg/mLintramuscular; intravenousHospira, Inc.1987-07-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycininjection, solution150 mg/mLintramuscular; intravenousHospira, Inc.1987-07-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycininjection, solution150 mg/mLintramuscular; intravenousHospira, Inc.1987-07-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycininjection, solution, concentrate150 mg/mLintravenousHospira, Inc.1987-07-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycininjection, solution, concentrate150 mg/mLintravenousHospira, Inc.1987-07-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycininjection, solution, concentrate150 mg/mLintravenousHospira, Inc.1987-07-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycininjection, solution, concentrate150 mg/mLintravenousHospira, Inc.1988-09-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamaxcream20 mg/gvaginalPHARMADERM. A division of Nycomed US Inc.2009-10-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamaxgel10 mg/gtopicalPharma Derm, A Division Of Nycomed Us Inc.2009-10-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clinda-dermsolution10 mg/mLtopicalPaddock Laboratoratories, LLC1992-10-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycininjection300 mg/50mLintravenousAkorn, Inc.2013-04-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycininjection600 mg/50mLintravenousAkorn, Inc.2013-04-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycininjection900 mg/50mLintravenousAkorn, Inc.2013-04-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycin Phosphatesolution10 mg/mLtopicalRebel Distributors Corp1997-06-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycininjection, solution150 mg/mLintramuscular; intravenousSagent Pharmaceuticals2012-05-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycininjection, solution150 mg/mLintravenousSagent Pharmaceuticals2012-05-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycin Phosphatesolution10 mg/mLtopicalPerrigo New York Inc2006-05-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycin Phosphatesolution10 mg/mLtopicalPerrigo New York Inc2013-09-17Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycin Phosphateaerosol, foam10 mg/gtopicalPerrigo New York Inc2010-03-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycin Phosphategel10 mg/gtopicalLake Erie Medical DBA Quality Care Products LLC2010-01-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycin Phosphatesolution10 mg/mLtopicalTaro Pharmaceuticals U.S.A., Inc.2004-03-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycininjection, solution150 mg/mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2010-01-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycin Phosphatesolution10 mg/mLtopicalPhysicians Total Care, Inc.2002-01-11Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycin Phosphateinjection, solution150 mg/mLintramuscular; intravenousPhysicians Total Care, Inc.1997-02-27Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycin Phosphategel10 mg/gtopicalPhysicians Total Care, Inc.2005-04-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycin Phosphatesolution10 mg/mLtopicalPhysicians Total Care, Inc.2003-06-04Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycin Phosphatelotion10 mg/mLtopicalPhysicians Total Care, Inc.2003-06-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycin Phosphatecream20 mg/gvaginalPhysicians Total Care, Inc.2005-05-19Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Cleocingranule, for solution75 mg/5mLoralPhysicians Total Care, Inc.2007-11-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycininjection, solution, concentrate150 mg/mLintravenousCardinal Health2011-06-09Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycininjection, solution150 mg/mLintramuscular; intravenousCardinal Health2012-05-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycin Phosphatesolution10 mg/mLtopicalVersa Pharm Incorporated2010-07-10Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycininjection, solution150 mg/mLintramuscular; intravenousAPP Pharmaceuticals, LLC2009-11-22Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycininjection, solution150 mg/mLintravenousAPP Pharmaceuticals, LLC2009-11-22Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycin Phosphategel10 mg/gtopicalPreferred Pharmaceuticals, Inc.2012-07-27Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Clindamycin Phosphatecream20 mg/gvaginalPreferred Pharmaceuticals, Inc.2012-03-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
ClindetsPerrigo
ClinimycinHayat
Dalacin CPfizer
Dalacin T Topical SolutionPfizer
ZindaclinCrawford
Brand mixtures
Brand NameIngredients
VELTINTretinoin + Clindamycin
Salts
Name/CASStructureProperties
Clindamycin Phosphate
24729-96-2
Thumb
  • InChI Key: UFUVLHLTWXBHGZ-KUWMELJBSA-N
  • Monoisotopic Mass: 504.146200983
  • Average Mass: 504.963
DBSALT000778
Categories
CAS number18323-44-9
WeightAverage: 424.983
Monoisotopic: 424.179870573
Chemical FormulaC18H33ClN2O5S
InChI KeyKDLRVYVGXIQJDK-NOWPCOIGSA-N
InChI
InChI=1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9?,10-,11+,12?,13+,14-,15-,16-,18-/m1/s1
IUPAC Name
(2S,4R)-N-{2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylsulfanyl)oxan-2-yl]propyl}-1-methyl-4-propylpyrrolidine-2-carboxamide
SMILES
CCC[C@@H]1C[C@H](N(C)C1)C(=O)NC(C(C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentAlpha amino acid amides
Alternative Parents
Substituents
  • Alpha-amino acid amide
  • S-glycosyl compound
  • Glycosyl compound
  • Pyrrolidine-2-carboxamide
  • Pyrrolidine carboxylic acid or derivatives
  • N-alkylpyrrolidine
  • Oxane
  • Monosaccharide
  • Saccharide
  • Pyrrolidine
  • Monothioacetal
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Secondary alcohol
  • Polyol
  • Carboxamide group
  • 1,2-diol
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Sulfenyl compound
  • Thioether
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Alkyl halide
  • Alkyl chloride
  • Alcohol
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of serious infections caused by susceptible anaerobic bacteria, including Bacteroides spp., Peptostreptococcus, anaerobic streptococci, Clostridium spp., and microaerophilic streptococci. May be useful in polymicrobic infections such as intra-abdominal or pelvic infections, osteomyelitis, diabetic foot ulcers, aspiration pneumonia and dental infections. May also be used to treat MSSA and respiratory infections caused by S. pneumoniae and S. pyogenes in patients who are intolerant to other indicated antibiotics or who are infected with resistant organism. May be used vaginally to treat vaginosis caused by Gardnerella vaginosa. Clindamycin reduces the toxin producing effects of S. aureus and S. pyogenes and as such, may be particularly useful for treating necrotizing fasciitis. May be used topically to treat acne.
PharmacodynamicsClindamycin is an antibiotic, similar to and a derivative of lincomycin. Clindamycin can be used in topical or systemic treatment. It is effective as an anti-anaerobic antibiotic and antiprotozoal.
Mechanism of actionSystemic/vaginal clindamycin inhibits protein synthesis of bacteria by binding to the 50S ribosomal subunits of the bacteria. Specifically, it binds primarily to the 23s RNA subunit. Topical clindamycin reduces free fatty acid concentrations on the skin and suppresses the growth of Propionibacterium acnes (Corynebacterium acnes) , an anaerobe found in sebaceous glands and follicles.
AbsorptionRapidly absorbed after oral administration with peak serum concentrations observed after about 45 minutes. Absorption of an oral dose is virtually complete (90%) and the concomitant intake of food does not appreciably modify the serum concentrations; serum levels have been uniform and predictable from person to person and dose to dose. Clindamycin does not penetrate the blood brain barrier.
Volume of distributionNot Available
Protein binding92-94%
Metabolism

Hepatic

Route of eliminationApproximately 10% of the bioactivity is excreted in the urine and 3.6% in the feces; the remainder is excreted as bioinactive metabolites.
Half life2.4 hours
ClearanceNot Available
ToxicityAdverse effects include nausea (may be dose-limiting), diarrhea, pseudomembranous colitis, allergic reactions, hepatoxicity, transient neutropenia and eosinophilia and agranulocytosis. Pseudomembranous colitis occurs in 0.01 - 10% of patients and occurs more commonly than with other antibiotics. Use of the topical formulation of clindamycin results in absorption of the antibiotic from the skin surface. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin.
Affected organisms
  • Enteric bacteria and other eubacteria
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8143
Blood Brain Barrier-0.9697
Caco-2 permeable-0.8236
P-glycoprotein substrateSubstrate0.7653
P-glycoprotein inhibitor INon-inhibitor0.7311
P-glycoprotein inhibitor IIInhibitor0.7894
Renal organic cation transporterNon-inhibitor0.8784
CYP450 2C9 substrateNon-substrate0.8214
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6762
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 substrateNon-inhibitor0.9071
CYP450 2D6 substrateNon-inhibitor0.9231
CYP450 2C19 substrateNon-inhibitor0.9025
CYP450 3A4 substrateNon-inhibitor0.8876
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9107
Ames testNon AMES toxic0.6967
CarcinogenicityNon-carcinogens0.9172
BiodegradationNot ready biodegradable0.994
Rat acute toxicity2.3192 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9887
hERG inhibition (predictor II)Non-inhibitor0.59
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Aerosol, foamtopical10 mg/g
Capsuleoral75 mg
Creamvaginal20 mg/g
Geltopical1 g/10mL
Geltopical10 mg/g
Geltopical10 mg/mL
Granule, for solutionoral75 mg/5mL
Injectionintravenous300 mg/50mL
Injectionintravenous600 mg/50mL
Injectionintravenous900 mg/50mL
Injection, solutionintramuscular; intravenous150 mg/mL
Injection, solutionintravenous150 mg/mL
Injection, solution, concentrateintravenous150 mg/mL
Lotiontopical10 mg/mL
Solutiontopical10 mg/mL
Suppositoryvaginal100 mg
Prices
Unit descriptionCostUnit
Clindagel 1% Gel 75ml Bottle324.48USD bottle
Evoclin 1% Foam 100 gm Can306.79USD can
Clindamycin Phosphate 1% Foam 100 gm Can286.04USD can
Evoclin 1% Foam 50 gm Can207.67USD can
Clindagel 1% Gel 40ml Bottle203.42USD bottle
Clindamycin Phosphate 1% Foam 50 gm Can186.9USD can
Clindamycin Phos-Benzoyl Perox 1-5% Gel 50 gm Jar176.42USD jar
Cleocin-T 1% Gel 60 gm Tube112.84USD tube
Cleocin-T 1% Lotion 60ml Bottle86.09USD bottle
Cleocin-T 60 1% Swab Box82.6USD box
Cleocin 2% Cream 40 gm Tube81.56USD tube
Cleocin 3 100 mg Suppository Box80.05USD box
Cleocin 75 mg/5ml Solution 100ml Bottle78.7USD bottle
Clindamycin hcl crystals74.9USD g
Clindamycin Phosphate 1% Gel 60 gm Tube71.42USD tube
Cleocin-T 1% Solution 60ml Bottle69.29USD bottle
Cleocin-T 1% Gel 30 gm Tube62.98USD tube
Clindamycin Phosphate 2% Cream 40 gm Tube54.99USD tube
Clindamycin Phosphate 60 1% Swab Box47.74USD box
Clindamycin Phosphate 1% Lotion 60ml Bottle46.92USD bottle
Clindesse 2% vaginal cream39.08USD g
Clindamycin Phosphate 1% Gel 30 gm Tube33.41USD tube
Clindamycin Phosphate 1% Solution 60ml Bottle24.07USD bottle
Clindamycin phosphate powdr21.42USD g
Clindamycin Phosphate 1% Solution 30ml Bottle14.99USD bottle
Cleocin hcl 300 mg capsule9.11USD capsule
Clindamycin phos crystals7.73USD g
Evoclin 1% foam4.9USD g
Clindagel 1% gel4.89USD ml
Cleocin 150 mg capsule4.66USD capsule
Dalacin C Phosphate 150 mg/ml4.53USD ml
Clindamycin hcl 300 mg capsule3.98USD capsule
Clindamycin phosphate 1% foam3.59USD g
Clindamycin 150 mg/ml3.48USD ml
Clindamycin (60 & 120 Ml) 150 mg/ml3.41USD ml
Cleocin hcl 150 mg capsule2.79USD capsule
Cleocin hcl 75 mg capsule2.28USD capsule
Dalacin C 300 mg Capsule2.12USD capsule
Cleocin 2% vaginal cream1.97USD g
Clindamycin 150 mg/ml addvan1.97USD ml
Cleocin phos 150 mg/ml vial1.91USD ml
Cleocin t 1% gel1.81USD g
Clindamycin ph 300 mg/2 ml vial1.74USD ml
Clindamax 2% vaginal cream1.37USD g
Clindamycin 2% vaginal cream1.27USD g
Clindamycin hcl 150 mg capsule1.21USD capsule
Clindets 1% pledgets1.1USD each
Dalacin C 150 mg Capsule1.06USD capsule
Apo-Clindamycin 300 mg Capsule1.02USD capsule
Mylan-Clindamycin 300 mg Capsule1.02USD capsule
Novo-Clindamycin 300 mg Capsule1.02USD capsule
Clindamycin ph 9 g/60 ml vial0.93USD ml
Apo-Clindamycin 150 mg Capsule0.51USD capsule
Mylan-Clindamycin 150 mg Capsule0.51USD capsule
Novo-Clindamycin 150 mg Capsule0.51USD capsule
Clinda-derm 1% solution0.4USD ml
Cleocin 900 mg-d5w-galaxy0.37USD ml
Cleocin 600 mg-d5w-galaxy0.3USD ml
Dalacin C Palmitate 15 mg/ml Solution0.14USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
United States52663291993-11-302010-11-30
United States73747472006-08-092026-08-09
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point142 [HCl salt]Not Available
water solubility30.6 mg/LNot Available
logP2.16HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility3.1 mg/mLALOGPS
logP1.76ALOGPS
logP1.04ChemAxon
logS-2.1ALOGPS
pKa (Strongest Acidic)12.16ChemAxon
pKa (Strongest Basic)7.55ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area102.26 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity105.72 m3·mol-1ChemAxon
Polarizability44.49 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Donald E. Ayer, Carl A. Schlagel, Gordon L. Flynn, “Topical clindamycin preparations.” U.S. Patent US4018918, issued January, 1971.

US4018918
General Reference
  1. Daum RS: Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med. 2007 Jul 26;357(4):380-90. Pubmed
  2. Klempner MS, Styrt B: Clindamycin uptake by human neutrophils. J Infect Dis. 1981 Nov;144(5):472-9. Pubmed
  3. Lamont RF: Can antibiotics prevent preterm birth—the pro and con debate. BJOG. 2005 Mar;112 Suppl 1:67-73. Pubmed
  4. Plaisance KI, Drusano GL, Forrest A, Townsend RJ, Standiford HC: Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate. Antimicrob Agents Chemother. 1989 May;33(5):618-20. Pubmed
External Links
ATC CodesD10AF01G01AA10J01FF01
AHFS Codes
  • 08:12.28.20
  • 84:04.04
PDB EntriesNot Available
FDA labelDownload (151 KB)
MSDSDownload (72.8 KB)
Interactions
Drug InteractionsNot Available
Food InteractionsNot Available

Targets

1. 50S ribosomal protein L10

Kind: protein

Organism: Shigella flexneri

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
50S ribosomal protein L10 P0A7J6 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Schlunzen F, Zarivach R, Harms J, Bashan A, Tocilj A, Albrecht R, Yonath A, Franceschi F: Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21. Pubmed

2. 23S rRNA

Kind: nucleotide

Organism: Enteric bacteria and other eubacteria

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details

References:

  1. Schlunzen F, Zarivach R, Harms J, Bashan A, Tocilj A, Albrecht R, Yonath A, Franceschi F: Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21. Pubmed

Enzymes

1. Cytochrome P450 3A4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:13